top of page

GynOnco Group | Ginecología Oncológica en Puerto Rico | Cuidado Experto y Compasivo"

Search

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005/TroFuse-005/GOG-3095)

GynOnco Group Team
Aug 15, 2025
1 min read

Updated: Aug 16, 2025

STUDY ID: NCT06132958

STATUS: Enrolling

CONDITION: Endometrial Cancer

SPONSOR: Merck Sharp & Dohme LLC

FOR MORE INFORMATION VISIT: https://www.clinicaltrials.gov/study/NCT06132958

Recent Posts

A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2

A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Can

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Can

bottom of page